Eloxx Pharmaceuticals, Inc. announced that the company has entered into a debt facility of up to $30.0 million with Hercules Capital, Inc. Eloxx has drawn the initial tranche of $12.5 million and used the proceeds to repay in full amounts outstanding under the company’s existing debt facility. The remaining funds under the new facility will be available in additional tranches upon the achievement of specific clinical milestones or other terms and conditions.